Loading
Life sciences · Journal article
Lipids in Health and Disease · September 11, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Lipoprotein(a) [Lp(a)] consists of an LDL-like particle that is covalently linked to apolipoprotein(a) [Apo(a)] through a disulfide bond. An elevated Lp(a) level is causally implicated in atherosclerotic cardiovascular disease (ASCVD). However, its clinical interpretation becomes more complex in metabolic disorders, including dyslipidemia, obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction-associated steatotic liver disease (MASLD). When elevated Lp(a) levels coexist with elevated LDL-C levels, obesity, or T2DM, the risk of ASCVD may be further increased. Accordingly, Lp(a) should be incorporated into the overall cardiovascular risk profile rather than assessed using a stand-alone cutoff. Conversely, emerging evidence has described a “low Lp(a) paradox,” in which very low Lp(a) levels have been reported in individuals with T2DM, MASLD, and advanced liver disease. These associations remain noncausal and may partly reflect insulin resistance, hyperinsulinemia, or impaired hepatic synthesis function. In addition, marked hypertriglyceridemia, hyperinsulinemia, and impaired liver function may transiently lower the measured Lp(a) concentrations, thereby masking the genetically determined Lp(a) burden and supporting the consideration of a reassessment after metabolic stabilization or an improvement in hepatic function in selected patients. This review summarizes the evidence linking Lp(a), metabolic disease, and ASCVD and, based on this integrated evidence, proposes an illustrative framework for interpreting the clinical significance of Lp(a) levels in patients with varying metabolic backgrounds within specific clinical contexts.